CONTROL BIONICS LIMITED Financials Control Bionics Limited
Equities
CBL
AU0000114183
Advanced Medical Equipment & Technology
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.05 AUD | +2.04% |
|
+16.28% | +8.70% |
| 09/05 | Control Bionics Appoints CFO | MT |
| 08/05 | Control Bionics Signs Multiple Award Schedule Contract with US Government | MT |
Valuation
| Fiscal Period: Juni | 2021 | 2022 | 2023 |
|---|---|---|---|
| Capitalization 1 | 58.04 | 19.56 | 7.872 |
| Enterprise Value (EV) 1 | 45.71 | 14.57 | 7.008 |
| P/E ratio | -12.3 x | -3.15 x | -1.39 x |
| Yield | - | - | - |
| Capitalization / Revenue | 14.2 x | 4.06 x | 1.4 x |
| EV / Revenue | 11.2 x | 3.03 x | 1.24 x |
| EV / EBITDA | -15.3 x | -2.55 x | -1.44 x |
| EV / FCF | -2,50,15,868 x | -27,12,297 x | -27,39,808 x |
| FCF Yield | -0% | -0% | -0% |
| Price to Book | 3.38 x | 1.64 x | 1.1 x |
| Nbr of stocks (in thousands) | 83,514 | 86,911 | 90,479 |
| Reference price 2 | 0.6950 | 0.2250 | 0.0870 |
| Announcement Date | 25/08/21 | 24/08/22 | 30/08/23 |
1AUD in Million2AUD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: Juni | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 0.8906 | 0.8963 | 3.3 | 4.088 | 4.815 | 5.642 |
| EBITDA 1 | -0.9684 | -1.927 | -0.9155 | -2.996 | -5.722 | -4.87 |
| EBIT 1 | -0.9731 | -1.936 | -1.003 | -3.149 | -6.139 | -5.235 |
| Operating Margin | -109.27% | -216.03% | -30.41% | -77.01% | -127.51% | -92.78% |
| Earnings before Tax (EBT) 1 | -0.9725 | -1.932 | -1.006 | -3.551 | -6.101 | -5.631 |
| Net income 1 | -0.9725 | -1.932 | -1.006 | -3.551 | -6.101 | -5.631 |
| Net margin | -109.19% | -215.51% | -30.47% | -86.85% | -126.72% | -99.8% |
| EPS | - | -0.2055 | -0.0983 | -0.0566 | -0.0715 | -0.0624 |
| Free Cash Flow | - | -1.202 | -0.8428 | -1.827 | -5.372 | -2.558 |
| FCF margin | - | -134.16% | -25.54% | -44.7% | -111.57% | -45.34% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 03/12/20 | 03/12/20 | 03/12/20 | 25/08/21 | 24/08/22 | 30/08/23 |
1AUD in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: Juni | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 1.84 | 0.8 | 1.15 | 12.3 | 4.99 | 0.86 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow | - | -1.2 | -0.84 | -1.83 | -5.37 | -2.56 |
| ROE (net income / shareholders' equity) | - | -34.7% | -18.7% | -31% | -42% | -59.1% |
| ROA (Net income/ Total Assets) | - | -20.6% | -10.7% | -15.9% | -24.1% | -29.6% |
| Assets 1 | - | 9.366 | 9.439 | 22.28 | 25.27 | 19.05 |
| Book Value Per Share | - | 0.5400 | 0.5600 | 0.2100 | 0.1400 | 0.0800 |
| Cash Flow per Share | - | 0.0800 | 0.1400 | 0.1500 | 0.0600 | 0.0100 |
| Capex 1 | 0.01 | 0.04 | 0.29 | 0.05 | 0.15 | 0.42 |
| Capex / Sales | 1.61% | 3.98% | 8.93% | 1.18% | 3.07% | 7.45% |
| Announcement Date | 03/12/20 | 03/12/20 | 03/12/20 | 25/08/21 | 24/08/22 | 30/08/23 |
1AUD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +8.70% | 5.63M | |
| -42.18% | 2.85B | |
| +22.02% | 1.94B | |
| +0.39% | 1.68B | |
| +27.15% | 1.26B | |
| -10.70% | 1.03B | |
| -18.27% | 938M | |
| +0.66% | 783M | |
| -25.07% | 628M | |
| +14.62% | 535M |
- Stock Market
- Equities
- CBL Stock
- Financials Control Bionics Limited
